Topic: chronic obstructive pulmonary disease (COPD)
4D will use its AAV vectors to create therapies that insert genes that code for therapeutic proteins into human cells.
An FDA advisory committee panel voted against recommending premarket approval for PneumRx’s Elevair lung implant for patients with severe emphysema.
The agreement gives AstraZeneca access to Owlstone’s breath biopsy services to support its search for asthma and COPD biomarkers.
The limited look at data from a small, short trial contains tidbits of encouragement but ultimately paints an inconclusive picture of RPL554.
If approved, Theravance and Mylan’s nebulized COPD drug would be the first once-daily, nebulized bronchodilator for COPD.
The trial’s success against eight out of nine lung function endpoints positions AstraZeneca to start filing for approval in the second half of 2018.
The move represents a big win for Propeller Health, which has a chance to provide its sensor-enabled inhaler and app to a large group of patients.
Data from the phase 2a trial suggest Verona’s PDE3/PDE4 inhibitor may complement long-acting muscarinic antagonist bronchodilators such as Spiriva.
GlaxoSmithKline and Propeller Health are expanding their R&D partnership, inked in 2015, into a commercial one.
The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva.